Business Wire

Ant International President Highlights AI and Connectivity as Key SME Growth Drivers

12.3.2025 12:19:00 CET | Business Wire | Press release

Share

Artificial Intelligence (AI) is being converted into flexible cross-border payment and digitisation solutions to help SMEs raise efficiency, lowering costs and controlling risks.More industry collaborations are needed to bridge payment systems and tech know-how.

Digital payment innovations are increasingly powerful tools for global businesses to raise productivity and turbocharge growth. The Digital Payment Market size1 is expected to grow at a CAGR of 11.8% and reach US$193.7 billion. However, there are digital divides and silos abound in core financial services for the global commerce system, especially in cross-border online and offline digital payment and settlement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312187829/en/

Douglas Feagin (left), President of Ant International, discussed payments innovation at GFTN Forum Japan in March 2025. (Photo: Business Wire)

“Even as technology advances in leaps and bounds, small businesses continue to face challenges in today’s digitised international transactions, from cross-border payment to cross-market growth,” said Douglas Feagin, President of Ant International, during the GFTN Forum held during the Japan Fintech Festival in Japan in March 2025. “We need to convert exciting developments in foundational technologies, such as AI, into comprehensive, effective and affordable solutions for the world’s long-tail business community.”

Ant International’s flagship Alipay+ cross-border mobile payment and digitisation technology has expanded to support 36 international payment apps, connecting over 90 million merchants across 66 markets. This “invisible” technology behind the cash register enables merchants to receive cross-border payments seamlessly and securely from individuals using their home e-wallets while maintaining competitive foreign exchange rates.

Interoperability is key, as local SMEs should be able to accept international payments more easily. In Asia, initiatives like national QRs have greatly boosted connectivity, and Alipay+ helps to bridge these infrastructures with our global payment partner users, but more needs to be done to bring together card and wallet-based ecosystems, Feagin said.

For SMEs, the capacity to accept various forms of international payments is not merely an advantage; it has become an essential factor for survival and growth in an increasingly competitive marketplace, Feagin noted.

Artificial Intelligence (AI) technology is crucial in addressing these pressing needs by providing tools that help SMEs make informed decisions swiftly, ensuring they meet customer demands while minimizing operational risks. A recent McKinsey report2 for 2025 underscores this importance, indicating that 92% of businesses plan to increase their AI investments this year. The consulting firm earlier predicted that companies integrating AI into their financial operations can expect productivity increases of up to 25%3.

At Ant International, AI-powered solutions are being developed to forecast currency demands based on transaction flows, enhancing efficiency in foreign exchange processes and steering the industry towards real-time payment systems.

For instance, Ant International’s AI-driven solution can forecast customers’ foreign-exchange needs with more than 90% accuracy based on provided data, which enables the company to help customers optimise their FX strategies.

As financial fraud becomes increasingly sophisticated, AI is paramount in safeguarding transactions. Ant International’s AI-powered risk management capabilities can effectively implement advanced fraud detection mechanisms that analyse patterns, identify anomalies, and protect against potential threats.

Interoperability will continue to be enhanced, particularly in Asia, where national QR systems and mobile wallets facilitate seamless transactions. This trend is expected to evolve rapidly as new LLM models are developed, enabling companies to streamline these workflows, said Feagin.

“We expect this revolution to continue at a rapid pace, and AI to accelerate efficiency and provide solutions for our customers,” added Feagin.

1https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html
2https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/superagency-in-the-workplace-empowering-people-to-unlock-ais-full-potential-at-work
3https://psico-smart.com/en/blogs/blog-how-can-artificial-intelligence-enhance-productivity-management-in-the-workplace-88579

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312187829/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye